These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10658682)

  • 21. Survey of early disapearance of BCR/ABL fusion transcript after allogeneic or autologous stem cell transplantation for chronic myelogenous leukemia.
    Vey N; Balatzentko G; Lafage M; Sainty D; Bouabdallah R; Chabannon C; Blaise D; Gastaut JA; Gabert J
    Leuk Lymphoma; 2001; 42(5):945-52. PubMed ID: 11697649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
    de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F
    Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive.
    Anastasi J; Musvee T; Roulston D; Domer PH; Larson RA; Vardiman JW
    Leukemia; 1998 Feb; 12(2):233-7. PubMed ID: 9519787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.
    Diekmann L; Beelen DW; Quabeck K; Becher R; Schulte Holthausen H; Bützler R; Schaefer UW; Opalka B
    Acta Haematol; 1994; 92(4):169-75. PubMed ID: 7701913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous stem cell transplantation in chronic myeloid leukemia.
    Olavarria E
    Semin Hematol; 2007 Oct; 44(4):252-8. PubMed ID: 17961724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
    Okamoto R; Harano H; Matsuzaki M; Motomura S; Maruta A; Kodama F; Mohri H; Okubo T
    Am J Clin Pathol; 1995 Nov; 104(5):510-6. PubMed ID: 7572810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bone marrow transplantation in chronic myeloid leukemia].
    Milone JH; Bordone J; Etchegoyen O; Napal J; Prates MV; Morales VH
    Medicina (B Aires); 1999; 59(1):1-10. PubMed ID: 10349111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML.
    Fischer T; Neubauer A; Mohm J; Huhn D; Busemann C; Link H; Arseniev L; Büssing B; Novotny J; Ganser A; Duyster J; Bunjes D; Kreiter S; Aulitzky W; Hehlmann R; Huber C
    Bone Marrow Transplant; 1998 May; 21(10):1029-36. PubMed ID: 9632277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of mixed chimerism to predict relapse in persistently BCR/ABL positive long survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Román J; Martín C; Torres A; García A; Andrés P; García MJ; Baiget M
    Leuk Lymphoma; 1998 Feb; 28(5-6):541-50. PubMed ID: 9613984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
    Sawyers CL; Timson L; Kawasaki ES; Clark SS; Witte ON; Champlin R
    Proc Natl Acad Sci U S A; 1990 Jan; 87(2):563-7. PubMed ID: 2405384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation.
    Lee M; Khouri I; Champlin R; Kantarjian H; Talpaz M; Trujillo J; Freireich E; Deisseroth A; Stass S
    Br J Haematol; 1992 Dec; 82(4):708-14. PubMed ID: 1482658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
    Hochhaus A; Lin F; Reiter A; Skladny H; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Br J Haematol; 1995 Sep; 91(1):126-31. PubMed ID: 7577619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
    Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
    Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
    Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.